Macular telangiectasia type 2

Macular telangiectasia type 2 is a condition affecting the small blood vessels around the macula, the central part of the retina, causing gradual changes in central vision. It typically affects both eyes and progresses slowly over many years.

The exact cause isn't fully understood, though it's thought to involve abnormalities in the small blood vessels and supporting cells around the macula, possibly with a genetic predisposition contributing in some cases. Research into the precise underlying mechanisms continues.

Symptoms include gradual blurring or distortion of central vision, difficulty reading small print, and sometimes a specific pattern of vision loss affecting one side of central vision more than the other. Progression is typically slow, occurring over many years.

It doesn't threaten peripheral vision or overall eye health beyond its effect on central vision, and progression is generally gradual rather than sudden. Regular monitoring helps track any changes and manage the condition appropriately over time.

There's some suggestion of a genetic contribution, as it can occasionally show a tendency to affect multiple family members, though most cases occur without a clear family history. Research into any specific genetic factors is ongoing.

There's currently no treatment that reverses the underlying condition, though regular monitoring helps track progression, and specific treatment may be considered if complications such as abnormal blood vessel growth develop. Low vision aids and support services can help manage the visual impact on daily activities.

Diagnosis typically involves detailed retinal imaging including optical coherence tomography and sometimes fluorescein angiography to visualise the characteristic blood vessel changes. Regular follow-up imaging monitors for progression or any complications requiring specific treatment.

It typically progresses slowly over many years, with gradual worsening of central vision, though the rate and pattern of progression varies between individuals. Regular ophthalmology monitoring helps track this progression and identify any need for specific intervention.

Both affect central vision through changes in the macula, but macular telangiectasia specifically involves abnormalities of the small blood vessels with a characteristic distinct appearance on imaging, distinguishing it from the different underlying processes seen in macular degeneration. Detailed retinal imaging by an ophthalmologist distinguishes between these different conditions.

Gradual, unexplained changes in central vision should be assessed by an ophthalmologist. Private ophthalmology consultations can typically be arranged within about two weeks, considerably faster than standard NHS waiting times.